Migraine drug Sumatriptan Actavis launched in Sweden
01.11.2006 - Actavis today announces the launch of Sumatriptan tablets in Sweden. Sumatriptan Actavis is the first generic version of the migraine drug to be made available in the country, and is being marketed immediately after patent expiry.
Sumatriptan, the generic equivalent of Glaxo SmithKline’s Imigran® and Imigran Novum®, is used for the relief of signs and symptoms of acute migraine. Sumatriptan Actavis is available in 50mg and 100mg coated tablets.
Sales of Imigran® and Imigran Novum® tablets in Sweden amount to EUR11.1 million, making Sumatriptan the mostly used 5-HT1-receptor agonist in this market.
Actavis has launched 23 new generic products in 2006 in the Nordic region, including Amlodipine and Glimepirid in Sweden and Finland, Zolpidem in Sweden, Tamsulosin in Denmark and Norway, and Lansoprazol in Finland.
Celebrating its 50th anniversary this year, Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in over 30 countries, with over 10,000 employees. The company’s market cap is approximately EUR2.9bn (US$3.6 billion) and it’s listed in the Iceland Stock Exchange. Actavis expects 2006 sales to total EUR1.4bn, with approximately 6% of these sales coming from the Nordic region.
- Contact Information
- Halldor Kristmannsson
- Media Contact
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.